Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16375)	10/30/2003 10:54:45 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Robert we agree 100%. When you say, " George, i think you like biogen but for the wrong reasons" Your reasons are of course wrong. I don;t like Biogen, Amevive, Mullen or even Kellog. Never ever said I like biogen. Nice to be in agreement about your being wrong, again and again. <g>

To: Robert K. who wrote (16375)	10/30/2003 12:09:03 PM
From: Cacaito	Respond to of 17367

Robert, Castello seems to plan to sell all the manufacturing capacity to the same group that bought the Rituxan Royalties Rights !!!

To: Robert K. who wrote (16375)	10/30/2003 12:24:39 PM
From: Cacaito	Respond to of 17367

Tifacogin, the data is out now, follow the main article and the editorial to appreciate Chiron saga and debacle with their sepsis product. Another sad end...or quasi end, which like bpi quasi end is even more painful. JAMA. 2003 Jul 9;290(2):238-47. Related Articles, Links Comment in: JAMA. 2003 Jul 9;290(2):256-8. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver 80262, USA. edward.abraham@uchsc.edu